Abstract
No public abstract is available from the verified source records.
Open public full textRights: UNKNOWN · cc-by-nc-nd · Source: journal-auto-sync:external:CROSSREF_ISSN
Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructurePradeep K. Gupta, Alexander A. Shestov, Neil Sen, Shilpa Rao, Stepan Orlovskiy, Fernando Arias-Mendoza, David S. Nelson, Mariusz A. Wasik
Abstract
Rights: UNKNOWN · cc-by-nc-nd · Source: journal-auto-sync:external:CROSSREF_ISSN
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Modulating glycolysis to improve cancer therapy
10.3390/ijms24032606 · 2023
Targeting the Warburg effect in cancer: where do we stand?
10.3390/ijms25063142 · 2024
Targeting cancer metabolism in the era of precision oncology
10.1038/s41573-021-00339-6 · 2022
Targeting energy metabolism in cancer treatment
10.3390/ijms23105572 · 2022
Targeting mitochondrial metabolism for precision medicine in cancer
10.1038/s41418-022-01022-y · 2022
Signaling pathways in cancer metabolism: mechanisms and therapeutic targets
10.1038/s41392-023-01442-3 · 2023
Emerging therapies in cancer metabolism
10.1016/j.cmet.2023.07.006 · 2023
Glutaminase inhibition as potential cancer therapeutics: current status and future applications
10.1080/14756366.2023.2290911 · 2024
Targeting glutamine metabolism as a therapeutic strategy for cancer
10.1038/s12276-023-00971-9 · 2023
Amino acid metabolism in tumor biology and therapy
10.1038/s41419-024-06435-w · 2024
Glutaminase - a potential target for cancer treatment
10.37796/2211-8039.1445 · 2024
crossref
Confidence 100%
pubmed
Confidence 98%
europepmc
Confidence 96%
unpaywall
Confidence 95%
datacite
Confidence 0%
Inhibition of glutaminase-1 in DLBCL potentiates venetoclax-induced antitumor activity by promoting oxidative stress
10.1182/bloodadvances.2023010964 · 2023
Preclinical investigations of the efficacy of the glutaminase inhibitor CB-839 alone and in combinations in chronic lymphocytic leukemia
10.3389/fonc.2023.1161254 · 2023
Inhibiting glutaminase in acute myeloid leukemia: metabolic dependency of selected AML subtypes
10.18632/oncotarget.12944 · 2016
The glutaminase inhibitor CB-839 targets metabolic dependencies of JAK2-mutant hematopoiesis in MPN
10.1182/bloodadvances.2023010950 · 2024
Emerging role of functional magnetic resonance spectroscopy (MRS) to monitor response to kinase inhibitors in cancer
2024
Frontline managment of mantle cell lymphoma
10.1182/blood.2023022352 · 2025
Novel treatment for mantle cell lymphoma - impact of BTK inhibitors and beyond
10.1080/10428194.2023.2264430 · 2024
Treatment of relapsed/refractory MCL
10.1182/blood.2023022353 · 2025
B cell-derived GABA elicits IL-10(+) macrophages to limit anti-tumour immunity
10.1038/s41586-021-04082-1 · 2021
GABAergic signaling by cells of the immune system: more the rule than the exception
10.1007/s00018-021-03881-z · 2021
B cells secrete GABA, which provokes a pro-tumor immune microenvironment
10.1016/j.ccell.2021.12.007 · 2022
Metabolic detection of Bruton's tyrosine kinase inhibition in mantle cell lymphoma cells
10.1158/1541-7786.mcr-18-0256 · 2019
Impact of therapeutic inhibition of oncogenic cell signaling tyrosine kinase on cell metabolism: in vivo-detectable metabolic biomarkers of inhibition
10.1186/s12967-024-05371-9 · 2024
No additional external references are available.